Press Release FeedGet the RSS feed
Menu

GlobeNewswire

U.S. Wireless Cardiac Monitoring Systems Market Size, Share, and Forecast 2026-2033 Featuring Profiles of Philips, iRhythm Technologies, Abbott, Medtronic, Biotronik (Teleflex) and More

Medtronic plc

Dublin, Oct. 20, 2026 -- "U.S. Wireless Cardiac Monitoring Systems Market Size, Share & Trends Analysis Report by Test Type, Product Type, Indication, End Use, Payer Type, and Growth Forecasts, 2026-2033" has been added to ResearchAndMarkets.com's offering.

The U.S. wireless cardiac monitoring systems market was valued at an estimated USD 2.4 billion in 2025 and is projected to reach USD 5.2 billion by 2033. The market is expected to expand at a compound annual growth rate of 10.1% from 2026 to 2033, supported by reimbursement expansion, increasing rates of cardiac rhythm disorders, and wider adoption of advanced remote monitoring technologies.

Growing reimbursement coverage for extended ECG services and remote cardiac monitoring is improving patient access to diagnostic testing across the United States. Payer-backed remote patient management programs are also encouraging healthcare providers to integrate connected monitoring solutions into routine cardiac care. These developments are expected to strengthen demand across hospitals, clinics, ambulatory centers, telehealth platforms, and home care settings.

AI-enabled wearable devices and patch-based monitoring systems are becoming increasingly important within the U.S. wireless cardiac monitoring systems market. These technologies support longer monitoring periods, efficient data analysis, and improved diagnostic accuracy. Cloud connectivity, real-time transmission, automated interpretation, and physician validation are also helping healthcare organizations manage cardiac data more effectively.

The continued shift toward outpatient and home-based monitoring is another major market driver. Telehealth integration enables providers to monitor patients beyond conventional clinical environments, while extended-wear devices support the detection of intermittent cardiac events. This transition is creating opportunities for medical device manufacturers, digital health companies, diagnostic service providers, and remote monitoring platforms.

Market Segmentation Covered in the Report

The report analyzes country-level revenue growth and key U.S. wireless cardiac monitoring systems market trends across sub-segments from 2021 to 2033. The analysis is organized by test type, product type, indication, end use, and payer type.

Test Type Outlook

  • Resting ECG and stress ECG
  • Holter monitoring across short-term (24-48 hours), intermediate (3-7 days), and long-term (>7 days) durations
  • On-device storage and cloud upload
  • Manual read, automated, and AI-assisted interpretation
  • Event monitoring through intermittent (patient-triggered) and continuous (auto-triggered) models
  • Offline Upload and real-time transmission
  • Mobile Cardiac Telemetry (MCT), including intermediate (48 hr-7 days) and long-term (>7 days) monitoring
  • Remote/Continuous ECG Monitoring, including long-term (>14 days) and continuous applications
  • Fully AI-assisted and physician-validated interpretation

Product Type Outlook

  • Implantable Cardiac Monitors (ICM), including Insertable Loop Recorders (ILRs) and long-life ICMs (>3 years)
  • Patch-Type Monitors with single-lead or multi-lead (3-12 leads) configurations
  • Single-use and reusable monitoring products
  • Mobile Cardiac Telemetry (MCT) offered through Patch + Service Bundles or Module + Subscription models
  • Holter Device systems with single-channel or multi-channel (3-12 channels) configurations
  • Wearable Consumer Devices/ Smartwatches, including FDA-cleared medical-grade and consumer-grade products
  • Other wireless cardiac monitoring products

Indication Outlook

  • Coronary artery disease
  • Angina pectoris
  • Atherosclerosis
  • Heart failure
  • Stroke / Transient Ischemic Attack (TIA)
  • Other cardiovascular indications

End Use and Payer Outlook

The report evaluates adoption across Hospitals & Clinics, Ambulatory / Diagnostic Centers, Telehealth Providers, Home Care Settings, Cardiac Rehabilitation Programs, and other care environments. Payer analysis covers Medicare, Medicaid, and Private Insurance, providing insight into how reimbursement structures influence technology adoption and patient access.

Strategic Value of the Report

  • Detailed U.S. market estimates and forecasts for informed decision-making
  • Analysis of growth opportunities, technology developments, and emerging industry trends
  • Revenue forecasts across test types, products, indications, end uses, and payer categories
  • Competitive landscape and market presence assessment of key participants
  • Evaluation of product innovation, AI-enabled monitoring, and remote care models
  • Actionable insights to support market entry, investment planning, product development, and revenue growth strategies

The report provides a focused assessment of the factors shaping the U.S. wireless cardiac monitoring systems market, including reimbursement policy, telehealth adoption, clinical demand, connected device innovation, and the expansion of home-based cardiac care.

Report AttributeDetails
No. of Pages100
Forecast Period2025-2033
Estimated Market Value (USD) in 2025$2.4 Billion
Forecasted Market Value (USD) by 2033$5.2 Billion
Compound Annual Growth Rate10.1%
Regions CoveredUnited States



Companies Featured

  • Koninklijke Philips N.V.
  • iRhythm Technologies, Inc.
  • Abbott
  • Medtronic
  • Biotronik (Teleflex)
  • Boston Scientific Corporation
  • Asahi Kasei Corporation
  • Avertix Medical, Inc.
  • Baxter
  • OSI Systems, Inc.
  • VivaQuant, Inc.
  • Rhythm Express

For more information about this report visit https://www.researchandmarkets.com/r/a3v751

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  1. AIGlobal Wearable Biosensors Market Trends, Strategies and Forecast to 2036 Featuring Abbott Labs, Dexcom, Medtronic, Roche, Apple, Samsung Electronics Co., Garmin and Other Key PlayersCompanies: DexcomGarmin Ltd.Medtronic plcRoche HoldingSamsung Electronics"Wearable Biosensors Market - Global Forecast to 2036" has been added to ResearchAndMarkets.com's offering. According to the research report, the global wearable biosensors market is projected to reach USD 105.5 billion by 2036 from USD 35.5 billion in 2026, growing at a CAGR of 12.5% during the forecast period (2026-2036). The growth of this market is primarily driven by the escalating demand for continuous health monitoring, the rising prevalence of chronic diseases such as diabetes and cardiovascular conditions, and the increasing adoption of personalized healthcare solutions. Wearable biosensors are sophisticated devices that enable real-time tracking of physiological parameters, providing critical data for early disease detection and remote patient management. The global wearable biosensors market is undergoing a profound structural transformation as the healthcare industry shifts from episodic, clinic-based care toward continuous, proactive health management. This evolution is being catalyzed by the rapid miniaturization of sensing technologies and the integration of advanced data analytics and artificial intelligence into consumer wearables. The industry is witnessing a significant transition from simple activity trackers toward medical-grade diagnostic devices that can monitor complex biomarkers like glucose, blood pressure, and cardiac rhythms with high precision. Furthermore, the integration of wearable biosensors with digital health and telemedicine platforms is creating a seamless ecosystem for remote patient monitoring and virtual care delivery. This dynamic shift ensures sustained demand for non-invasive, user-friendly sensing solutions that empower individuals and healthcare providers with actionable health insights, ultimately improving clinical outcomes and reducing healthcare costs. Market Segmentation The global wearable biosensors market is segmented by biomarker type (glucose monitoring, heart rate and cardiac biomarkers, blood oxygen [SpO2] monitoring, blood pressure monitoring, lactate and performance biomarkers, and other biomarkers), product type/form factor (smartwatches, fitness bands, continuous glucose monitoring devices, wearable ECG monitors, smart patches, smart rings, and smart clothing), application (clinical and medical, fitness and wellness, and sports and performance monitoring), end-user (hospitals and clinics, home care settings, fitness and sports organizations, individual consumers, and research institutions), and geography. The study evaluation includes industry competitors and analyzes the market at the country level. Based on Biomarker Type By biomarker type, the glucose monitoring segment is expected to hold the largest share of the global wearable biosensors market in 2026. This dominance is attributed to the high and rising prevalence of diabetes globally and the widespread adoption of continuous glucose monitoring (CGM) systems that eliminate the need for frequent finger-prick testing. Conversely, the heart rate and cardiac biomarkers segment is projected to register significant growth, driven by the increasing integration of ECG and heart rate variability (HRV) sensing into consumer smartwatches, enabling early detection of arrhythmias and other cardiovascular conditions. Furthermore, the lactate and multi-analyte biosensors segments are projected to register the highest CAGR during the forecast period, fueled by the growing demand for performance optimization in sports and the development of non-invasive sensors for comprehensive metabolic health tracking. Based on Product Type / Form Factor By product type/form factor, the smartwatches with integrated biosensors segment is expected to hold the largest share of the global wearable biosensors market in 2026. Smartwatches have become the primary platform for health monitoring due to their high consumer acceptance, multi-functionality, and the continuous addition of medical-grade sensors by leading tech companies. Meanwhile, the continuous glucose monitoring devices segment is projected to register the highest CAGR during the forecast period. This rapid growth is driven by the shift toward proactive diabetes management and the expansion of CGM use among non-insulin-dependent patients and health-conscious individuals. Additionally, smart patches and smart rings are emerging as high-growth segments, offering discrete and specialized monitoring for clinical and wellness applications. Based on Application By application, the clinical and medical segment is expected to hold the largest share in 2026. The increasing use of wearable biosensors for chronic disease management, post-operative monitoring, and clinical trials drives this segment's leadership. Within this segment, remote patient monitoring (RPM) is a major growth catalyst. Conversely, the fitness and wellness segment is projected to register a steady growth rate, driven by the increasing consumer focus on preventive health and the popularity of activity and sleep tracking. The sports and performance monitoring segment is also witnessing rapid expansion as professional athletes and fitness enthusiasts adopt biosensors to optimize training and recovery through data-driven insights. Based on End-User By end-user, the hospitals and clinics segment is expected to hold the largest share in 2026, reflecting the primary role of healthcare providers in prescribing and managing medical-grade wearable sensors for patient care. Conversely, the home care settings segment is projected to register the highest CAGR during the forecast period. This rapid growth is driven by the global trend toward decentralized healthcare and the increasing preference for monitoring patients in their home environments to improve comfort and reduce hospital readmissions. The individual consumers segment also remains significant, as more people purchase wearables for personal health and fitness tracking. Geographic Analysis In 2026, North America is expected to account for the largest share of the global wearable biosensors market. The region's leadership is underpinned by a highly advanced healthcare infrastructure, high levels of digital health literacy, and the presence of industry leaders such as Abbott, Dexcom, Apple, and Medtronic in the United States. Furthermore, the early adoption of remote patient monitoring and a favorable reimbursement landscape for digital health technologies contribute to the market's dominance. Key companies in the North America market include Abbott Laboratories (U.S.), Dexcom, Inc. (U.S.), Apple Inc. (U.S.), Medtronic plc (Ireland), Garmin Ltd. (U.S.), Google LLC (Fitbit - U.S.), Masimo Corporation (U.S.), VitalConnect, Inc. (U.S.), and Biolinq Inc. (U.S.). Asia-Pacific is projected to witness the fastest growth during the forecast period. This expansion is primarily driven by increasing healthcare expenditure, the rapid expansion of the middle-class population, and the high penetration of smartphones and wearable devices in China, India, and Japan. Furthermore, the rising burden of chronic diseases in the region and government initiatives to promote digital health are significant catalysts. Key companies in the Asia-Pacific market include Samsung Electronics Co., Ltd. (South Korea) and various emerging local MedTech startups. Europe remains a critical market for wearable biosensors, characterized by a strong focus on preventive healthcare and the implementation of robust medical device regulations. European countries are increasingly adopting wearable sensors to address the healthcare needs of an aging population and to improve the efficiency of public health systems. The region's focus on data privacy and security is driving the demand for sensors that comply with strict GDPR and MDR standards. Key companies in the Europe market include F. Hoffmann-La Roche Ltd. (Switzerland), Oura Health Ltd. (Finland), and Empatica Inc. (U.S./Italy). Latin America is an emerging market for wearable biosensors, driven by the modernization of healthcare facilities and the increasing adoption of consumer health technologies in Brazil and Mexico. The region is seeing a shift toward more accessible health monitoring solutions as enterprises and individuals seek to manage chronic conditions more effectively. The Middle East & Africa region is experiencing growing interest in wearable biosensors as part of national digital health transformation strategies, particularly in the UAE and Saudi Arabia. Investments in high-tech healthcare infrastructure and the adoption of AI-driven health solutions are expected to be major drivers of market growth in the region. Key Players The key players operating in the global wearable biosensors market include:
  2. FinanceSpolečnost Cornerstone Robotics oznamuje strategické partnerství se společností Medtronic s cílem rozšířit globální dostupnost roboticky asistované chirurgieCompanies: Medtronic plcHONGKONG, 2. září 2026 -- Společnost Cornerstone Robotics, inovativní firma zabývající se chirurgickou robotikou, která byla založena v Hongkongu a má tam také své sídlo, dnes oznámila strategické partnerství se společností Medtronic (NYSE: MDT), vedoucím globálním podnikem v...
  3. FinanceCornerstone Robotics ogłasza strategiczne partnerstwo z Medtronic mające na celu zwiększenie dostępu do chirurgii robotycznej na świecieCompanies: Medtronic plcHONGKONG, 2 września 2026 r. -- Cornerstone Robotics, innowacyjna firma z branży robotyki chirurgicznej założona i mająca siedzibę w Hongkongu, ogłosiła dziś strategiczne partnerstwo z Medtronic (NYSE: MDT), światowym liderem technologii medycznych. W ramach współpracy...
  4. FinanceCornerstone Robotics Announces Strategic Partnership with Medtronic to Expand Global Access to Robotic-assisted SurgeryCompanies: Medtronic plcHONG KONG, Sep 1, 2026 - Cornerstone Robotics, an innovative surgical robotics company founded and headquartered in Hong Kong, today announced a strategic partnership with Medtronic (NYSE: MDT), a global leader in healthcare technology. As part of the partnership, Medtronic will make an approximately US$700 million strategic investment in Cornerstone Robotics and have rights to distribute Cornerstone Robotics’ SentireTM surgical system in select markets outside the U.S. where the system is market approved. A Shared Vision: Bridging the Global Access Gap in Minimally Invasive Care With robotic-assisted surgery adoption still in single digits globally, the opportunity to make advanced surgical care accessible to more patients, physicians, and health systems around the world is significant. Addressing this market requires both continuous technical innovation and strong market scaling capabilities. By aligning Cornerstone Robotics’ technology with Medtronic’s comprehensive global presence, the two companies aim to make high-quality robotic-assisted surgery accessible to more patients worldwide. A Strategic Alignment: Scaling Technology Solutions to Reach More Patients Cornerstone Robotics has established a strong strategic foundation through its full-stack in-house R&D and vertically integrated paradigm. By independently developing its core hardware, control software, advanced algorithms, and proprietary imaging and energy platforms, Cornerstone Robotics maintains substantial control over product integration, quality, and supply chain resilience. This underpins the exceptional stability and high-fidelity performance of the Sentire surgical system in demanding clinical environments. In 2024, Cornerstone Robotics’ Sentire surgical system received National Medical Products Administration approval in China. In May 2026, Sentire surgical system received CE Mark in the European Union and approval from Singapore Health Sciences Authority, both covering minimally invasive general, gynecologic, thoracic, and urologic surgical procedures. “This partnership marks an important step in advancing access to robotic-assisted surgery around the world,” said Professor Kwok Wai Samuel AU, Founder and CEO of Cornerstone Robotics. “There remains a significant gap between the growing demand for minimally invasive surgery and the availability of robotic-assisted surgical technologies. At Cornerstone Robotics, we have built a strong foundation through full-stack in-house R&D and vertical integration, enabling us to continuously advance the core technologies of surgical robotics. Our partnership with Medtronic positions us to further accelerate and scale our work to bring the benefits of robotic-assisted surgery to more surgeons and patients around the world.” “This investment and distribution agreement strengthens Medtronic’s ability to further expand access to minimally invasive surgery to more patients around the world. We’re excited to bring more choice in robotics, and Sentire is a strong complement to our Hugo platform," said Matt Anderson, Senior Vice President and President, Surgical at Medtronic. The partnership marks a significant milestone for both companies to collaboratively advance their shared mission of making robotic-assisted surgery more accessible worldwide. Advisors Kirkland & Ellis and Global Law Office are acting as legal counsel to Cornerstone Robotics. Morgan Stanley & Co. LLC is serving as exclusive financial advisor to Medtronic, and Cleary Gottlieb Steen & Hamilton LLP is serving as lead legal counsel. About Cornerstone Robotics Founded and headquartered in Hong Kong, Cornerstone Robotics is an innovative surgical robotics company driven by the vision of leading medical innovations for a healthier world. We advance surgical care with cutting-edge robotic systems that make high-quality healthcare more accessible and efficient globally. With three global R&D hubs and six business centres worldwide, Cornerstone Robotics has established a 30,000-square-meter manufacturing facility in China. Developed entirely in-house, our SentireTM surgical system has completed multi-specialty clinical trials and received market approval across China, the European Union and Singapore, advancing high-quality surgical care worldwide. To find out more information, please visit https://en.csrbtx.com/ and follow us on LinkedIn. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow on LinkedIn.
  5. FinanceCornerstone Robotics Announces Strategic Partnership with Medtronic to Expand Global Access to Robotic-assisted SurgeryCompanies: Medtronic plcHONG KONG, Sep 1, 2026 - Cornerstone Robotics, an innovative surgical robotics company founded and headquartered in Hong Kong, today announced a strategic partnership with Medtronic (NYSE: MDT), a global leader in healthcare technology. As part of the partnership, Medtronic will make an approximately US$700 million strategic investment in Cornerstone Robotics and have rights to distribute Cornerstone Robotics’ SentireTM surgical system in select markets outside the U.S. where the system is market approved. A Shared Vision: Bridging the Global Access Gap in Minimally Invasive Care With robotic-assisted surgery adoption still in single digits globally, the opportunity to make advanced surgical care accessible to more patients, physicians, and health systems around the world is significant. Addressing this market requires both continuous technical innovation and strong market scaling capabilities. By aligning Cornerstone Robotics’ technology with Medtronic’s comprehensive global presence, the two companies aim to make high-quality robotic-assisted surgery accessible to more patients worldwide. A Strategic Alignment: Scaling Technology Solutions to Reach More Patients Cornerstone Robotics has established a strong strategic foundation through its full-stack in-house R&D and vertically integrated paradigm. By independently developing its core hardware, control software, advanced algorithms, and proprietary imaging and energy platforms, Cornerstone Robotics maintains substantial control over product integration, quality, and supply chain resilience. This underpins the exceptional stability and high-fidelity performance of the Sentire surgical system in demanding clinical environments. In 2024, Cornerstone Robotics’ Sentire surgical system received National Medical Products Administration approval in China. In May 2026, Sentire surgical system received CE Mark in the European Union and approval from Singapore Health Sciences Authority, both covering minimally invasive general, gynecologic, thoracic, and urologic surgical procedures. “This partnership marks an important step in advancing access to robotic-assisted surgery around the world,” said Professor Kwok Wai Samuel AU, Founder and CEO of Cornerstone Robotics. “There remains a significant gap between the growing demand for minimally invasive surgery and the availability of robotic-assisted surgical technologies. At Cornerstone Robotics, we have built a strong foundation through full-stack in-house R&D and vertical integration, enabling us to continuously advance the core technologies of surgical robotics. Our partnership with Medtronic positions us to further accelerate and scale our work to bring the benefits of robotic-assisted surgery to more surgeons and patients around the world.” “This investment and distribution agreement strengthens Medtronic’s ability to further expand access to minimally invasive surgery to more patients around the world. We’re excited to bring more choice in robotics, and Sentire is a strong complement to our Hugo platform," said Matt Anderson, Senior Vice President and President, Surgical at Medtronic. The partnership marks a significant milestone for both companies to collaboratively advance their shared mission of making robotic-assisted surgery more accessible worldwide. Advisors Kirkland & Ellis and Global Law Office are acting as legal counsel to Cornerstone Robotics. Morgan Stanley & Co. LLC is serving as exclusive financial advisor to Medtronic, and Cleary Gottlieb Steen & Hamilton LLP is serving as lead legal counsel. About Cornerstone Robotics Founded and headquartered in Hong Kong, Cornerstone Robotics is an innovative surgical robotics company driven by the vision of leading medical innovations for a healthier world. We advance surgical care with cutting-edge robotic systems that make high-quality healthcare more accessible and efficient globally. With three global R&D hubs and six business centres worldwide, Cornerstone Robotics has established a 30,000-square-meter manufacturing facility in China. Developed entirely in-house, our SentireTM surgical system has completed multi-specialty clinical trials and received market approval across China, the European Union and Singapore, advancing high-quality surgical care worldwide. To find out more information, please visit https://en.csrbtx.com/ and follow us on LinkedIn. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow on LinkedIn.
  6. FinanceCornerstone Robotics Announces Strategic Partnership with Medtronic to Expand Global Access to Robotic-assisted SurgeryCompanies: Medtronic plcCornerstone Robotics, an innovative surgical robotics company founded and headquartered in Hong Kong, today announced a strategic partnership with Medtronic (NYSE: MDT), a global leader in healthcare technology. As part of the partnership,...